Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
293 questions in 51 reviews · ENT
current versionsNo studies 293 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Adverse eventsb · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Vertigo/dizziness: timing not reported · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Ear pain: timing not reported · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic corticosteroids vs no treatment or versus placebo Adverse eventsb · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic corticosteroids vs no treatment or versus placebo Vertigo/dizziness: timing not reported · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic corticosteroids vs no treatment or versus placebo Ear pain: timing not reported · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Change in hearing threshold determined by PTA · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Final hearing threshold determined by PTA · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Adverse eventsb · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Vertigo/dizziness: timing not reported · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Vertigo/dizziness: at the time of injection · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Ear pain: timing not reported · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic plus systemic corticosteroids (combined therapy) vs systemic corticosteroids alone Ear pain: at the time of injection · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Intratympanic corticosteroids vs systemic corticosteroids Adverse eventsb · sudden sensorineural hearing loss Intratympanic corticosteroids for sudden sensorineural hearing loss (2022) · Cochrane | no estimate extracted | NR | No studies |
Antihistamines vs scopolamine Proportion of susceptible participants who experienced a reduction or resolution of existing motion sickness symptoms · patients with motion sickness Antihistamines for motion sickness (2022) · Cochrane | no estimate extracted | NR | No studies |
Antihistamines vs scopolamine Physiological measures: core temperature and gastric tachyarrhythmia (electrogastrography) · patients with motion sickness Antihistamines for motion sickness (2022) · Cochrane | no estimate extracted | NR | No studies |
Antihistamines vs scopolamine Adverse effects: impaired cognitive function · patients with motion sickness Antihistamines for motion sickness (2022) · Cochrane | no estimate extracted | NR | No studies |
Antihistamines vs antiemetics Proportion of susceptible participants who experienced a reduction or resolution of existing motion sickness symptoms · patients with motion sickness Antihistamines for motion sickness (2022) · Cochrane | no estimate extracted | NR | No studies |
Antihistamines vs antiemetics Physiological measures: heart rate and core temperature · patients with motion sickness Antihistamines for motion sickness (2022) · Cochrane | no estimate extracted | NR | No studies |
Antihistamines vs antiemetics Adverse effects: impaired cognition and blurred vision · patients with motion sickness Antihistamines for motion sickness (2022) · Cochrane | no estimate extracted | NR | No studies |
Antihistamines vs acupuncture Proportion of susceptible participants who experienced a reduction or resolution of existing motion sickness symptoms · patients with motion sickness Antihistamines for motion sickness (2022) · Cochrane | no estimate extracted | NR | No studies |
Antihistamines vs acupuncture Physiological measures: heart rate, core temperature and gastric tachyarrhythmia (electrogastrography) · patients with motion sickness Antihistamines for motion sickness (2022) · Cochrane | no estimate extracted | NR | No studies |
Antihistamines vs acupuncture Adverse effects: sedation, impaired cognitive function, blurred vision · patients with motion sickness Antihistamines for motion sickness (2022) · Cochrane | no estimate extracted | NR | No studies |
Antihistamines vs placebo Proportion of susceptible participants who experienced a reduction or resolution of existing motion sickness symptoms · patients with motion sickness Antihistamines for motion sickness (2022) · Cochrane | no estimate extracted | NR | No studies |
Antihistamines vs placebo Physiological measures: heart rate and core temperature · patients with motion sickness Antihistamines for motion sickness (2022) · Cochrane | no estimate extracted | NR | No studies |
Gingko biloba with concurrent intervention vs concurrent intervention only Other adverse effects (gastrointestinal upset, headache, allergic reaction) · adults with tinnitus Ginkgo biloba for tinnitus (2022) · Cochrane | no estimate extracted | NR | No studies |
Gingko biloba with concurrent intervention vs concurrent intervention only Serious adverse effects (bleeding or seizures) · adults with tinnitus Ginkgo biloba for tinnitus (2022) · Cochrane | no estimate extracted | NR | No studies |
Gingko biloba with concurrent intervention vs concurrent intervention only Health‐related quality of life · adults with tinnitus Ginkgo biloba for tinnitus (2022) · Cochrane | no estimate extracted | NR | No studies |
Palmitoylethanolamide and luteolin vs no intervention Generic quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Palmitoylethanolamide and luteolin vs no intervention Presence of parosmia · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention Generic quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Systemic corticosteroids plus intranasal steroid/mucolytic/decongestant vs no intervention Presence of parosmia · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Palmitoylethanolamide and luteolin vs no intervention Disease‐related quality of life · adults with olfactory dysfunction for ≥ 4 weeks following COVID‐19 infection Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid drops vs placebo Serious adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid drops vs placebo Change in sense of smell · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid drops vs placebo Prevalence of parosmia · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid drops vs placebo Change in sense of taste · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid drops vs placebo Disease‐related quality of life · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid drops vs placebo Other adverse effects · participants with olfactory dysfunction following COVID‐19 for ≤ 15 days Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid spray vs no intervention/placebo Prevalence of parosmia · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid spray vs no intervention/placebo Change in sense of taste · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Intranasal steroid spray vs no intervention/placebo Disease‐related quality of life · people with olfactory dysfunction for less than 4 weeks following COVID‐19 infection Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction (2022) · Cochrane | no estimate extracted | NR | No studies |
Systemic antibiotics vs no treatment or placebo on top of topical antibiotics Health‐related quality of life · people (of any age) with CSOM Systemic antibiotics for chronic suppurative otitis media (2021) · Cochrane | no estimate extracted | NR | No studies |
Systemic antibiotics vs no treatment or placebo on top of topical antibiotics Hearing · people (of any age) with CSOM Systemic antibiotics for chronic suppurative otitis media (2021) · Cochrane | no estimate extracted | NR | No studies |
Systemic antibiotics vs no treatment or placebo on top of topical antibiotics Resolution of ear discharge ‐ measured at 1 to 2 weeks · people with CSOM; one study included patients of unknown age; one study included children with CSOM who had not… Systemic antibiotics for chronic suppurative otitis media (2021) · Cochrane | no estimate extracted | NR | No studies |
Systemic antibiotics vs no treatment or placebo on top of topical antibiotics Ear pain (otalgia) or discomfort or local irritation · people with CSOM; one study included patients of unknown age; one study included children with CSOM who had not… Systemic antibiotics for chronic suppurative otitis media (2021) · Cochrane | no estimate extracted | NR | No studies |
Systemic antibiotics vs no treatment/placebo Resolution of ear discharge ‐ measured after 4 weeks · children with CSOM Systemic antibiotics for chronic suppurative otitis media (2021) · Cochrane | no estimate extracted | NR | No studies |
Systemic antibiotics vs no treatment or placebo on top of topical antibiotics Suspected ototoxicity · people with CSOM; one study included patients of unknown age; one study included children with CSOM who had not… Systemic antibiotics for chronic suppurative otitis media (2021) · Cochrane | no estimate extracted | NR | No studies |
Systemic antibiotics vs no treatment or placebo on top of topical antiseptics Resolution of ear discharge ‐ measured between 1 week and up to 2 weeks · schoolchildren with CSOM Systemic antibiotics for chronic suppurative otitis media (2021) · Cochrane | no estimate extracted | NR | No studies |